Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11684
Title: Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.
Austin Authors: Holmes, Natasha E ;Turnidge, J D;Munckhof, Wendy J;Robinson, J O;Korman, Tony M;O'Sullivan, Matthew V N;Anderson, Tara L;Roberts, S A;Warren, S J C;Gao, W;Johnson, Paul D R ;Howden, Benjamin P 
Affiliation: Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Infectious Diseases
Issue Date: 26-Feb-2013
Publication information: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2013; 19(12): 1163-8
Abstract: We reported an association between elevated vancomycin MIC and 30-day mortality in patients with Staphylococcus aureus bacteraemia (SAB), including patients with methicillin-susceptible S. aureus (MSSA) treated with flucloxacillin. A detailed analysis of comorbidities and disease severity scores in the same cohort of patients was performed to ascertain if unknown clinical parameters may have influenced these results. The association between elevated vancomycin MIC and 30-day mortality in SAB remained significant (p 0.001) on multivariable logistic regression analysis even when accounting for clinical factors. In addition, the association persisted when restricting analysis to patients with MSSA bacteraemia treated with flucloxacillin. This suggests that elevated vancomycin MIC is associated with but not causally linked to an organism factor that is responsible for increased mortality.
URI: https://ahro.austin.org.au/austinjspui/handle/1/11684
DOI: 10.1111/1469-0691.12168
ORCID: 
Journal: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
URL: https://pubmed.ncbi.nlm.nih.gov/23441652
Type: Journal Article
Subjects: Bacteraemia
Staphylococcus aureus
comorbidity
mortality
vancomycin minimum inhibitory concentration
Adolescent
Adult
Aged
Anti-Bacterial Agents.pharmacology.therapeutic use
Bacteremia.drug therapy.microbiology.mortality
Child
Child, Preschool
Comorbidity
Female
Humans
Infant
Infant, Newborn
Logistic Models
Male
Methicillin-Resistant Staphylococcus aureus.drug effects
Microbial Sensitivity Tests
Middle Aged
Retrospective Studies
Staphylococcal Infections.drug therapy.microbiology.mortality
Staphylococcus aureus.drug effects
Treatment Outcome
Vancomycin.pharmacology.therapeutic use
Young Adult
Appears in Collections:Journal articles

Show full item record

Page view(s)

8
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.